Come and visit us at McCormick Place in Chicago to discover how our state-of-the-art microCT, real-time 3D autoradiography, and multispectral imaging system can expand your clinical applications. Together, we can explore how the unique micro-scale imaging capabilities of MILabs’, multi-modality imaging platform can deliver a ‘stepchange’ improvement in diagnostic imaging of small clinical specimens, with near histological levels of detail.
MILabs imaging system sales are on a roll, globally
After receiving the recent WMIC 2018 Innovation of the Year award, MILabs’ high-resolution broadband photon tomography PET/SPECT/Optical/CT system sales are thriving worldwide. New systems have been acquired and installed in Israel, India, North America, Australia, and Europe. Pre-clinical researchers appreciate the expansion and high reliability of the high-resolution VECTor6 platform, including its exclusive applications such as simultaneous multi-isotope PET/PET and PET/SPECT imaging, 3D Optical/CT and ultra-high resolution DCE-CT imaging with soft-tissue segmentation.
MILabs has a long history of innovation and advanced product support enabling its customers to achieve new levels of imaging functionality. Among recently published innovative applications are:
For the first time, whole-body dynamic PET imaging of the 18F‐radiolabeled isotopologue of the Food and Drug Administration‐approved PARP inhibitor olaparib. J. Nuc. Med. November 2, 2018. “PET imaging of PARP expression using 18F‐olaparib”. T.C. Wilson et al., University of Oxford, Oxford, UK. Read more
Characterization of a novel chelating ligand as an alternative to traditionally used DTPA and DOTA. J. Am. Chem. Soc. October 16, 2018. “H4octox: Versatile Bimodal Octadentate Acyclic Chelating Ligand for Medicinal Inorganic Chemistry”. X. Wang et al., University of British Columbia, Vancouver, British Columbia, Canada.Read more
Development of imaging-guided enhanced cancer radioisotope therapy using chelator-free radiolabeling chemistry on a biocompatible & biodegradable nanoplatform. ACS Nano, October 25, 2018. “Calcium Bisphosphonate Nanoparticles with Chelator-Free Radiolabeling to Deplete Tumor-Associated Macrophages for Enhanced Cancer Radioisotope Therapy”. L. Tian et al., Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou, Jiangsu, China. Read more
Dynamic whole-body SPECT imaging for personalized chemotherapeutic drug toxicity monitoring and management. Clin. Cancer Res. November 12, 2018. “Whole-body imaging of cell death provides a systemic, minimally invasive, dynamic and near-real time indicator for chemotherapeutic drug toxicity.”, S.E. Johnson et al., Northwestern University, Northbrook, IL, USA. Read more
SPECT/CT fusion images show the gut region in control (Con) and cisplatin (CDDP) treated animals, with corresponding H&E and TUNEL images which demonstrated tissue degeneration and the elevation of apoptosis. (from S.E. Johnson et al. Clin Cancer Res, 2018)
Meet us at:
RSNA, November 25 – 30, Chicago, IL, USA
Arab Health, January 28 – 31 2019, Dubai, UAE
EMIM, March 19 – 22 2019, Glasgow, United Kingdom
AACR, March 30 – April 3 2019, Atlanta, GA, USA
NukMed, April 3 – 6 2019, Bremen, Germany
MPIC,April 28 – 30 2019, Evanston, IL, USA
ISRS, May 26 – 31 2019, Beijing, China
SNMMI, June 22 – 25 3 2019, Anaheim, CA, USA
MILabs products are used in more than 65 countries and are supported by a global network of distributors and factory trained support engineers.
Please contact MILabs directly for more information about your local MILabs business partner.